The NOX1/ NOX4 inhibitor setanaxib, which indirectly affects ENaC, is tested in clinical phase 2 and 3 trials for therapy of primary biliary cholangitis, liver stiffness and squamous cell carcinoma of the head and neck. Here, NOX1 is linked to biliary liver cirrhosis.